Xenitra’s Q3 Sales Jump 300% Fueled by $30M Danone Partnership

Sales Recovery and Growth Momentum

Xenitra Limited (ASX:XEN) reported a dramatic rebound in sales during Q3 2026, with preliminary unaudited figures showing a surge to $8.3 million, more than triple the $2.0 million recorded in Q2. This jump was primarily driven by the Nutritionals segment, which benefited from the recently inked $30 million strategic partnership with Rockcheck Group for Danone products. In March alone, sales exceeded $4 million, signaling a near full recovery to the company’s FY24 annualised sales levels after a year of restructuring and turnaround efforts.

Strategic Partnerships Cement Revenue Base

The Rockcheck deal not only secures a substantial revenue floor for the Nutritionals division but also granted Xenitra’s Australian subsidiary approved supplier status across Rockcheck’s wider conglomerate. This opens the door to additional product sales beyond Danone, potentially expanding revenue streams in the coming year. This development aligns with Xenitra’s broader strategy of leveraging established distribution channels across Asia’s FMCG, nutraceuticals, and OTC medicine markets. The significance of this milestone is underscored by the prior announcement of the $30M Danone Deal that laid the groundwork for this partnership.

New Divisions Target Higher Margins

Beyond Nutritionals, Xenitra has launched two new divisions focused on OTC Medicines and blockchain tokenised sales, which Chairman Anthony Noble highlighted as “completely new sources of future revenue growth” with significantly higher gross margins. While these divisions did not materially contribute to Q3 sales, they are expected to begin generating revenue in Q4. The OTC Medicines business was bolstered by the recent acquisition of Hong Kong-based Fukang Trading, providing key pharmaceutical licenses and ecommerce assets to support expansion in China’s lucrative OTC market. This acquisition was detailed in the company’s prior filing on the Hong Kong OTC Pharmacy acquisition.

Innovating with Blockchain Tokenised Sales

Xenitra’s blockchain initiative, launched under the OPAL token brand, represents a pioneering Web3 sales ecosystem linking real-world FMCG and nutraceutical products with a tokenised digital commerce platform. This system aims to enhance product authentication, customer loyalty, and sales transparency across Asian markets. The OPAL token was introduced recently and is designed to function as a utility and membership token tied directly to product sales, creating a novel revenue channel that leverages blockchain technology. This innovation was outlined in the company’s earlier announcement on the OPAL Token launch.

Outlook Amid Transition and Renewal

After a challenging year of business restructuring, Xenitra appears to have established a leaner, more focused operational model with multiple growth avenues. The company’s diverse distribution network across B2B wholesale, retail, and ecommerce platforms in Asia underpins its ability to scale these new initiatives. However, the financial impact of the OTC and blockchain divisions remains to be seen in upcoming quarters. Investors will be watching how these innovative sales channels translate into tangible revenue and margin expansion as Xenitra moves into Q4 and beyond.